Latest research on Ifosfamide

Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppresive agent.

Latest findings

Ifosfamide and Doxorubicin are the most frequently used chemotherapeutic agents in patients with mediastinal liposarcoma. [source, 2016]
The first‐line chemotherapy for advanced, metastatic, or non‐resectable soft tissue sarcoma is typically based on DOX as a single agent or in combination with a second drug such as Ifosfamide. [source, 2016]
For refractory thymoma and thymic carcinoma, the NCCN guidelines [12] recommend single-agent or non-platinum-based chemotherapy, such as Etoposide [25], Gemcitabine [26], Paclitaxel [27], Ifosfamide [28], Pemetrexed [29], 5-Fluorouracil (5-FU) and Leucovorin [30], and Octreotide (including long acting-formulation) plus Prednisolone [31]. [source, 2016]
Some patients received postoperative radiation and/or chemotherapy (generally Doxorubicin and Ifosfamide) based on prognostic factors predicting higher risk of local recurrence and distant metastasis. [source, 2016]
Systemic chemotherapies for GEP-NET included Octreotide, VIP (vincristine, Ifosfamide, Cisplatin), XELOX (Capecitabine, Oxaliplatin), EP (Etoposide, Cisplatin), pazopanib, Sunitinib, everolimus, and XELIRI (Capecitabine, Irinotecan). [source, 2016]
revealed that combination of Doxorubicin, Ifosfamide, and Mesna was associated with a significant improvement in disease-specific survival in patients with high-grade extremity soft tissue sarcomas. [source, 2016]
found that anthracyclines have a degree of antitumor activity in the range of soft tissue sarcoma chemotherapy, but Ifosfamide monotherapy seemed to have lower activity. [source, 2016]
First-line LMS chemotherapy currently consists of Doxorubicin (Dox), an anthracycline that inhibits topoisomerase II thereby disrupting DNA repair, in combination with Ifosfamide [9]. [source, 2016]
Several drugs can induce FS, such as Tenofovir, Ifosfamide, aminoglycoside antibiotics and FAEs (see Table 1) [7, 10]. [source, 2016]
However, correlation analysis revealed significant relationships between increasing oculomotor deficits and cumulative dosages of the three chemotherapy agents; Cisplatin, methotrexate and Ifosfamide. [source, 2016]